2013 (4) TMI 348 - SC - Indian Laws

Supreme Court rules against Novartis on Imatinib patent, reinforcing standards to prevent patent evergreening

The Supreme Court dismissed the appeals filed by Novartis AG, holding that the beta crystalline form of Imatinib Mesylate did not qualify as an invention ... Interpretation of section 3(d) as a patentability threshold for pharmaceutical polymorphs - definition of 'invention' under clauses (j) and (ja) of section 2(1) - requirement of enhancement of known efficacy for a new form of a known substance - treatment of salts, esters, polymorphs and other derivatives as the same substance unless they differ significantly in properties with regard to efficacy (Explanation to section 3(d)) - novelty and inventive step in light of prior patent disclosure (anticipation by Zimmermann patent) - reconciling TRIPS obligations with domestic public health safeguards in patent lawDefinition of 'invention' under clauses (j) and (ja) of section 2(1) - novelty and inventive step in light of prior patent disclosure (anticipation by Zimmermann patent) - Meaning and constituent tests of 'invention' under section 2(1)(j) and (ja) of the Patents Act, 1970. - HELD THAT: - The Court held that to qualify as an 'invention' under section 2(1)(j) a product must be (i) 'new' (not anticipated), (ii) involve an 'inventive step' as defined in section 2(1)(ja) (a feature involving technical advance over existing knowledge or economic significance and making the invention not obvious to a person skilled in the art), and (iii) be capable of industrial application. The Court emphasised the distinctness of the concepts of 'invention' and 'patentability' and analysed the definition in the context of the statute's history and the policy concerns that shaped the 2005 amendments.A product must satisfy novelty, an inventive step (technical advance/non obviousness) and industrial applicability to be an 'invention' under section 2(1)(j) and (ja).Novelty and inventive step in light of prior patent disclosure (anticipation by Zimmermann patent) - Whether Imatinib Mesylate (non crystalline salt) is a new product outside the Zimmermann patent and therefore an 'invention' under section 2(1). - HELD THAT: - On the materials before the Court (the Zimmermann patent, contemporaneous scientific publications, regulatory filings and the appellant's own conduct), the Court found that Imatinib Mesylate was disclosed in and formed part of the Zimmermann patent and that its pharmacological properties were already known from that prior disclosure and related publications. The Court rejected the appellant's submission that the Zimmermann patent merely 'covered' but did not 'disclose' Imatinib Mesylate in an enabling manner, observing that the objective record (including regulatory submissions and litigation conduct) supported the conclusion that Imatinib Mesylate was known.Imatinib Mesylate is a known substance from the Zimmermann patent and thus does not satisfy the novelty/invention requirement under section 2(1)(j)/(ja).Interpretation of section 3(d) as a patentability threshold for pharmaceutical polymorphs - requirement of enhancement of known efficacy for a new form of a known substance - treatment of salts, esters, polymorphs and other derivatives as the same substance unless they differ significantly in properties with regard to efficacy (Explanation to section 3(d)) - Whether the claimed beta crystalline form of Imatinib Mesylate is patentable in view of section 3(d) and its Explanation. - HELD THAT: - The Court held that section 3(d) operates as a statutory check (a second tier standard) on patentability of new forms of known chemical/pharmaceutical substances to prevent 'evergreening'. The provision requires that a new form of a known substance must result in an enhancement of the known efficacy of that substance; the Explanation treats salts, esters, polymorphs, isomers and the like as the same substance unless they differ significantly in properties with regard to efficacy. The Court examined the appellant's evidence: the asserted advantages of the beta form (better flow, thermodynamic stability, lower hygroscopicity) concern processability and storage and do not, by themselves, establish enhanced therapeutic efficacy. The affidavits asserting increased bioavailability (in animals) were insufficient to establish enhanced therapeutic efficacy over Imatinib Mesylate (the known substance immediately preceding the beta form). The Court noted that increased bioavailability alone does not automatically translate into enhanced therapeutic efficacy absent specific evidence proving that the increased bioavailability produces a meaningful therapeutic improvement.The beta crystalline form of Imatinib Mesylate fails section 3(d) because the claimed advantages do not demonstrate enhancement of the known therapeutic efficacy of the known substance; patentability under section 3(d) is therefore excluded.Final Conclusion: The Court dismissed Novartis AG's appeals: Imatinib Mesylate was held to be known from the Zimmermann patent and not an 'invention' under section 2(1)(j)/(ja), and the claimed beta crystalline form failed the statutory requirement in section 3(d) (no proven enhancement of known therapeutic efficacy). The decision does not mean that all incremental pharmaceutical inventions are unpatentable; rather, where a new form of a known pharmaceutical does not significantly enhance known efficacy it is excluded from patentability under section 3(d). Issues Involved:1. Interpretation of Section 3(d) of the Patents Act, 1970.2. The interplay between Section 3(d) and Clauses (j) and (ja) of Section 2(1).3. Patentability of the beta crystalline form of Imatinib Mesylate.4. Compliance with international treaties and obligations.5. Impact on public health and access to life-saving drugs.Detailed Analysis:1. Interpretation of Section 3(d) of the Patents Act, 1970:The central issue was the interpretation of Section 3(d) of the Patents Act, 1970, which aims to prevent the 'evergreening' of patents by disallowing patents for new forms of known substances unless they result in enhanced efficacy. The Court noted that Section 3(d) was amended to set a higher standard for patentability, particularly for pharmaceutical products. The amendment was intended to strike a balance between encouraging genuine innovation and preventing the extension of patent monopolies on trivial grounds.2. The Interplay Between Section 3(d) and Clauses (j) and (ja) of Section 2(1):The Court examined whether the beta crystalline form of Imatinib Mesylate qualified as an 'invention' under Clauses (j) and (ja) of Section 2(1). It was determined that for a product to qualify as an invention, it must be new, involve an inventive step, and be capable of industrial application. The inventive step must entail a technical advance over existing knowledge or have economic significance, making the invention non-obvious to a person skilled in the art.3. Patentability of the Beta Crystalline Form of Imatinib Mesylate:The Court found that Imatinib Mesylate was a known substance from the Zimmermann patent, and its pharmacological properties were already known. The beta crystalline form of Imatinib Mesylate did not exhibit enhanced efficacy over the known substance, Imatinib Mesylate. The Court emphasized that the properties such as better flow, stability, and lower hygroscopicity, while beneficial, did not qualify as enhanced therapeutic efficacy under Section 3(d).4. Compliance with International Treaties and Obligations:The Court acknowledged India's obligations under international treaties like the TRIPS Agreement but emphasized that the Indian patent law must be interpreted on its own terms. The TRIPS Agreement and the Doha Declaration allow member states to adopt measures necessary to protect public health. The Court noted that the Indian patent law, as amended, was fully TRIPS compliant and aimed to balance international obligations with public health considerations.5. Impact on Public Health and Access to Life-Saving Drugs:The Court highlighted the importance of ensuring that life-saving drugs remain accessible to the public. It was noted that the introduction of product patents for pharmaceuticals could potentially put essential medicines beyond the reach of many, particularly in developing and underdeveloped countries. The Court emphasized that the legislative intent behind Section 3(d) was to prevent the extension of patent monopolies on frivolous grounds and to ensure that genuine innovations that enhance therapeutic efficacy are encouraged.Conclusion:The Supreme Court dismissed the appeals filed by Novartis AG, holding that the beta crystalline form of Imatinib Mesylate did not qualify as an invention under the Patents Act, 1970, and failed the test of Section 3(d). The judgment underscored the importance of maintaining a high standard for patentability to prevent the evergreening of patents and ensure access to affordable medicines.